Literature DB >> 864480

Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.

A Galea-Debono, P Jenner, C D Marsden, J D Parkes, D Tarsy, J Walters.   

Abstract

It has been suggested that the therapeutic response to levodopa in patients with Parkinson's disease may be related to changes in plasma growth hormone concentration. In order to examine this problem, we have determined plasma DOPA and growth hormone levels after a standard oral levodopa load in 32 patients with Parkinson's disease. Levodopa caused an increase in plasma growth hormone concentration in 30 subjects. The magnitude and timing of this growth hormone response was not related to the clinical response, the presence or absence of response swings, or the occurrence of dyskinesias. The growth hormone response to levodopa is normal in patients with Parkinson's disease and not altered by long-term levodopa treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 864480      PMCID: PMC492632          DOI: 10.1136/jnnp.40.2.162

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

1.  A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA.

Authors:  D S SCHALCH; M L PARKER
Journal:  Nature       Date:  1964-09-12       Impact factor: 49.962

2.  An in vitro study of biomechanical changes produced by hypermetabolism and hypometabolism in skeletal muscle.

Authors:  E H Denys; W W Hofmann
Journal:  Neurology       Date:  1972-01       Impact factor: 9.910

3.  Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy.

Authors:  W B Malarkey; J Cyrus; G W Paulson
Journal:  J Clin Endocrinol Metab       Date:  1974-08       Impact factor: 5.958

4.  Corticosteroid and growth hormone secretion in patients treated with L-dopa.

Authors:  K von Werder; G R van Loon; F Yatsu; P H Forsham
Journal:  Klin Wochenschr       Date:  1970-12-15

5.  Bromocriptine in Parkinsonism.

Authors:  D B Calne; P F Teychenne; L E Claveria; R Eastman; J K Greenacre; A Petrie
Journal:  Br Med J       Date:  1974-11-23

6.  Postmenopausal bleeding: another side-effect of levodopa.

Authors:  C Kruse-Larsen; K Garde
Journal:  Lancet       Date:  1971-04-03       Impact factor: 79.321

7.  Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.

Authors:  R D Sweet; F H McDowell
Journal:  Neurology       Date:  1974-10       Impact factor: 9.910

8.  "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.

Authors:  S Fahn
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

9.  "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321

10.  Effect of levodopa (L-DOPA) on human hypophyseal tropic hormone release.

Authors:  R L Eddy; A L Jones; Z H Chakmakjian; M C Silverthorne
Journal:  J Clin Endocrinol Metab       Date:  1971-10       Impact factor: 5.958

View more
  3 in total

1.  Growth hormone secretion in empty sella syndrome.

Authors:  K Brismar
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

Review 2.  Bromocriptine in the treatment of parkinsonism.

Authors:  J D Parkes
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

3.  Endocrine aspects of bromocriptine therapy in Parkinsonism.

Authors:  K M Shaw; A J Lees; S Franks; P Daggett; B D Thompson; G M Stern
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.